Tags

Type your tag names separated by a space and hit enter

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.
Mult Scler. 2015 Jan; 21(1):22-34.MS

Abstract

Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II). Important adverse events were infusion-associated reactions, serious infections and autoimmune events. A safety monitoring program allowed for early detection and management of autoimmune events. Recommendations for the monitoring of adverse events are made. Alemtuzumab's mechanism of action, pharmacodynamics and opportunities for future research are discussed.

Authors+Show Affiliations

Department of Neurology and Center for Neuropsychiatry, Medical Faculty, Heinrich-Heine University, Germany hans-peter.hartung@uni-duesseldorf.de.Department of Neurology and Center for Neuropsychiatry, Medical Faculty, Heinrich-Heine University, Germany.Moscow City Center of Multiple Sclerosis, Russian Federation, Russia.

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

25344374

Citation

Hartung, Hans-Peter, et al. "Alemtuzumab: a New Therapy for Active Relapsing-remitting Multiple Sclerosis." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 21, no. 1, 2015, pp. 22-34.
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):22-34.
Hartung, H. P., Aktas, O., & Boyko, A. N. (2015). Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 21(1), 22-34. https://doi.org/10.1177/1352458514549398
Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a New Therapy for Active Relapsing-remitting Multiple Sclerosis. Mult Scler. 2015;21(1):22-34. PubMed PMID: 25344374.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. AU - Hartung,Hans-Peter, AU - Aktas,Orhan, AU - Boyko,Alexey N, Y1 - 2014/10/24/ PY - 2014/10/26/entrez PY - 2014/10/26/pubmed PY - 2015/11/14/medline KW - Alemtuzumab KW - CD52 KW - monoclonal antibody KW - multiple sclerosis SP - 22 EP - 34 JF - Multiple sclerosis (Houndmills, Basingstoke, England) JO - Mult Scler VL - 21 IS - 1 N2 - Alemtuzumab is a humanized monoclonal antibody directed against CD52 to deplete circulating T and B lymphocytes; lymphocyte depletion is followed by a distinctive pattern of T- and B-cell repopulation, changing the balance of the immune system. This review reports the efficacy and safety findings of the phase 2 CAMMS223 trial and the phase 3 CARE-MS I and II trials investigating alemtuzumab for the treatment of active relapsing-remitting MS. Alemtuzumab, administered intravenously, was shown to improve relapse rate versus subcutaneous interferon beta-1a in patients who were treatment-naive (CAMMS223 and CARE-MS I) or had relapsed on prior therapy (CARE-MS II), and to reduce sustained accumulation of disability (CAMMS223 and CARE-MS II). Important adverse events were infusion-associated reactions, serious infections and autoimmune events. A safety monitoring program allowed for early detection and management of autoimmune events. Recommendations for the monitoring of adverse events are made. Alemtuzumab's mechanism of action, pharmacodynamics and opportunities for future research are discussed. SN - 1477-0970 UR - https://www.unboundmedicine.com/medline/citation/25344374/Alemtuzumab:_a_new_therapy_for_active_relapsing_remitting_multiple_sclerosis_ L2 - https://journals.sagepub.com/doi/10.1177/1352458514549398?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -